Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00325689 · ClinicalTrials.gov registry record · Phase 4
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
A Phase 4 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 4
- Development phase
- 323
- Enrollment target
NCT00325689 is a Phase 4 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 323 participants.
The verdict
NCT00325689, a Phase 4 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 323 participants
- Enrollment target
Study Summary
A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
Interventions
- DRUG Quetiapine or Risperidone + Aripiprazole
- DRUG Quetiapine or Risperidone + placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00325689
The ClinicalTrials.gov registry entry for NCT00325689 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 323 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quetiapine or Risperidone + Aripiprazole is the first listed.
NCT00325689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00325689 about?
NCT00325689 is a clinical study titled "Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.". A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
What is the current status of trial NCT00325689?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 323 participants. The study started on 2006-07. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00325689?
The interventions under investigation include: Quetiapine or Risperidone + Aripiprazole (DRUG), Quetiapine or Risperidone + placebo (DRUG).
Who is sponsoring clinical trial NCT00325689?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.